تاثیر دویدن روی چرخ دوار پیچیده بر بتا آمیلوئید، نپریلیسین خون، بیان کبدی LRP1 و PPARγ در موش های صحرایی مدل بیماری آلزایمر
تاثیر دویدن بر بتا آمیلوئید، نپریلیسین LRP1 و PPARγ در آلزایمر
محورهای موضوعی : تشخیص مولکولی نشانگر های بیوشیمیایی و ژنتیکی
نادیا تاجوانچی
1
,
رسول اسدی هاشم کندی
2
,
رقیه پوزش
3
,
فرزاد زهساز
4
,
کریم آزالی علمداری
5
1 - دانشجوی دکتری تخصصی فیزیولوژی ورزشی دانشگاه آزاد تبریز
2 - عضو هیأت علمی گروه علوم ورزشی، واحد تبریز، دانشگاه آزاد اسلامی
3 - استادیارگروه تربیت بدنی دانشگاه آزاد تبریز
4 - هیئت علمی آزاد تبریز
5 - دانشگاه شهید مدنی
کلید واژه: چرخ دوار پیچیده, بتا آمیلوئید, نپریلیسین خون, بیان کبدی LRP1, PPARγ, بیماری آلزایمر,
چکیده مقاله :
زمینه و هدف: ورزش و فعالیت بدنی می تواند در به تاخیر انداختن آلزایمر نقش موثری داشته باشد. مکانیسم های مولکولی متعددی توسط فعالیت های بدنی مختلف فعال می شوند که شاخص های زوال عقل را تقلیل می دهند و هدف از پژوهش حاضر بررسی تاثیر دویدن روی چرخ دوار پیچیده بر بتا آمیلوئید، نپریلیسین خون، بیان کبدی LRP1 و PPARγ در موش های صحرایی مدل بیماری آلزایمر بود. مواد و روش ها: 24 موش صحرایی به صورت تصادفی انتخاب و در سه گروه: کنترل سالم، گروه کنترل آلزایمری و گروه آلزایمر+ تمرین چرخ گردان پیچیده تقسیم شدند. گروه تمرینی به اجرای 12 هفته تمرین پرداختند وگروه کنترل نیز به مدت 12 هفته در قفس نگهداری شدند و در هيچ تمرينی شركت داده نشدند. تمرین موش ها روی چرخ دوار پیچیده و به مدت 12 هفته بود، همچنین در انتهای هفته 12 موش ها مبتلا به آلزایمر شده و از آن ها تست های شاتل باکس جهت اطمینان از القا بیماری آلزایمر گرفته شد. در این تحقیق به منظور بررسی تغییرات کبدی متغییر های یاد شده به روش آلایزا مورد بررسی قرار گرفت. به منظور تجزیه و تحلیل داده‌ها از آزمون تحلیل واریانس یک راهه استفاده شد. نتایج: نتایج نشان داد تفاوت معنی داری بین بتا آمیلوئید و بیان کبدی LRP1 موش های صحرایی گروه آلزایمر کنترل با بتا آمیلوئید و بیان کبدی LRP1 موش های صحرایی گروه تمرین چرخ پیچیده وجود ندارد. اما تفاوت معنی داری بین نپریلیسین خون PPARγ موش های صحرایی گروه آلزایمر کنترل با نپریلیسین خون و PPARγ موش های صحرایی گروه تمرین چرخ پیچیده وجود دارد. نتیجه گیری: استفاده از فعالیت بدنی می تواند نپریلیسین خون و PPARγ را در موش های صحرایی بهبود بخشد اما بهبود بتا آمیلوئید و بیان کبدی LRP1 نیازمند پژوهش های بیشتر می باشد. کلمات کلیدی: چرخ دوار پیچیده، بتا آمیلوئید، نپریلیسین خون، بیان کبدی LRP1، PPARγ، بیماری آلزایمر
Background & Aim: Exercise and physical activity can play an effective role in delaying Alzheimer's. Multiple molecular mechanisms are activated by different physical activities that reduce dementia indices. The purpose of this study was to investigate the effect of running on a Complex wheel running on beta-amyloid, blood neprilysin, and liver expression of LRP1 and PPARγ in Alzheimer's disease model rats. Materials & Methods: 24 rats were randomly selected and divided into three groups: healthy control, Alzheimer's control group, and Alzheimer's + complex spinning wheel training group. The training group performed 12 weeks of training and the control group was kept in a cage for 12 weeks and did not participate in any training. The rats were trained on a Complex wheel running for 12 weeks, and at the end of the 12th week, the rats were diagnosed with Alzheimer's and shuttle box tests were used to ensure the induction of Alzheimer's disease. In this research, in order to investigate liver changes, the mentioned variables were investigated by ELISA method. In order to analyze the data, one-way analysis of variance test was used. Results: The results showed that there is no significant difference between beta-amyloid and liver LRP1 expression of Alzheimer's control group rats and beta-amyloid and liver LRP1 expression of rats in the Complex wheel running training group. However, there is a significant difference between blood neprilysin of PPARγ rats in the control Alzheimer's group and neprilysin blood and PPARγ of rats in the complex wheel training group. Conclusion: Using physical activity can improve blood neprilysin and PPARγ in rats, but the improvement of beta-amyloid and liver LRP1 expression requires more research.
1. Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid\beta-protein. Journal of Alzheimer's disease. 2001 Feb 1;3(1):75-82.
2. Dawkins E, Small DH. Insights into the physiological function of the β‐amyloid precursor protein: beyond Alzheimer's disease. Journal of neurochemistry. 2014 Jun;129(5):756-69.
3. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D. β-amyloid monomers are neuroprotective. Journal of Neuroscience. 2009 Aug 26;29(34):10582-7.
4. Giuffrida, M. L Giuffrida ML, Tomasello MF, Pandini G, Caraci F, Battaglia G, Busceti C, Di Pietro P, Pappalardo G, Attanasio F, Chiechio S, Bagnoli S. Monomeric ß-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons. Frontiers in cellular neuroscience. 2015 Aug 7;9:297.
5. Zimbone S, Monaco I, Gianì F, Pandini G, Copani AG, Giuffrida ML, Rizzarelli E. Amyloid Beta monomers regulate cyclic adenosine monophosphate response element binding protein functions by activating type‐1 insulin‐like growth factor receptors in neuronal cells. Aging Cell. 2018 Feb;17(1):e12684.
6. Spencer B, Rockenstein E, Crews L, Marr R, Masliah E. Novel strategies for Alzheimer's disease treatment. Expert opinion on biological therapy. 2007 Dec 1;7(12):1853-67.
7. Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimer's research & therapy. 2020 Dec;12:1-0.
8. Campos CR, Kemble AM, Niewoehner J, Freskgård PO, Urich E. Brain shuttle neprilysin reduces central amyloid-β levels. Plos one. 2020 Mar 10;15(3):e0229850.
9. Rofo F, Yilmaz CU, Metzendorf N, Gustavsson T, Beretta C, Erlandsson A, Sehlin D, Syvänen S, Nilsson P, Hultqvist G. Enhanced neprilysin-mediated degradation of hippocampal Aβ42 with a somatostatin peptide that enters the brain. Theranostics. 2021;11(2):789.
10. Sikanyika NL, Parkington HC, Smith AI, Kuruppu S. Powering amyloid beta degrading enzymes: a possible therapy for Alzheimer’s disease. Neurochemical Research. 2019 Jun 15;44:1289-96.
11. Miners JS, Barua N, Kehoe PG, Gill S, Love S. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. Journal of Neuropathology & Experimental Neurology. 2011 Nov 1;70(11):944-59.
12. Devault A, Lazure C, Nault C, Le Moual H, Seidah NG, Chretien M, Kahn P, Powell J, Mallet J, Beaumont A. Amino acid sequence of rabbit kidney neutral endopeptidase 24.11 (enkephalinase) deduced from a complementary DNA. The EMBO Journal. 1987 May;6(5):1317-22.
13. Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, Higuchi M, Staufenbiel M, Muramatsu SI, Saido TC. Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Scientific reports. 2013 Mar 18;3(1):1472.
14. Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS. Expression and functional profiling of neprilysin, insulin‐degrading enzyme, and endothelin‐converting enzyme in prospectively studied elderly and Alzheimer’s brain. Journal of neurochemistry. 2010 Oct;115(1):47-57.
15. Kuruppu S, Rajapakse NW, Minond D, Smith AI. Production of soluble Neprilysin by endothelial cells. Biochemical and biophysical research communications. 2014 Apr 4;446(2):423-7.
16. Howell S, Nalbantoglu J, Crine P. Neutral endopeptidase can hydrolyze β-amyloid (1–40) but shows no effect on β-amyloid precursor protein metabolism. Peptides. 1995 Jan 1;16(4):647-52.
17. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain Aβ by neprilysin. Science. 2001 May 25;292(5521):1550-2.
18. Takaki Y, Iwata N, Tsubuki S, Taniguchi S, Toyoshima S, Lu B, Gerard NP, Gerard C, Lee HJ, Shirotani K, Saido TC. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid β peptide in the brain. The journal of biochemistry. 2000 Dec 1;128(6):897-902.
19. Madani R, Poirier R, Wolfer DP, Welzl H, Groscurth P, Lipp HP, Lu B, Mouedden ME, Mercken M, Nitsch RM, Mohajeri MH. Lack of neprilysin suffices to generate murine amyloid‐like deposits in the brain and behavioral deficit in vivo. Journal of neuroscience research. 2006 Dec;84(8):1871-8.
20. Mouri A, Zou LB, Iwata N, Saido TC, Wang D, Wang MW, Noda Y, Nabeshima T. Inhibition of neprilysin by thiorphan (icv) causes an accumulation of amyloid β and impairment of learning and memory. Behavioural brain research. 2006 Mar 15;168(1):83-91.
21. Newell AJ, Sue LI, Scott S, Rauschkolb PK, Walker DG, Potter PE, Beach TG. Thiorphan-induced neprilysin inhibition raises amyloid β levels in rabbit cortex and cerebrospinal fluid. Neuroscience letters. 2003 Oct 30;350(3):178-80.
22. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003 Dec 18;40(6):1087-93.
23. Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Shinohara M, Holtzman DM, Bu G. Neuronal clearance of amyloid-β by endocytic receptor LRP1. Journal of Neuroscience. 2013 Dec 4;33(49):19276-83.
24. Liu CC, Hu J, Zhao N, Wang J, Wang N, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G. Astrocytic LRP1 mediates brain Aβ clearance and impacts amyloid deposition. Journal of Neuroscience. 2017 Apr 12;37(15):4023-31.
25. Storck SE, Hartz AM, Bernard J, Wolf A, Kachlmeier A, Mahringer A, Weggen S, Pahnke J, Pietrzik CU. The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM. Brain, behavior, and immunity. 2018 Oct 1;73:21-33.
26. Pflanzner T, Janko MC, André-Dohmen B, Reuss S, Weggen S, Roebroek AJ, Kuhlmann CR, Pietrzik CU. LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier. Neurobiology of aging. 2011 Dec 1;32(12):2323-e1.
27. Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. Journal of Neuroscience. 2004 Apr 28;24(17):4259-65.
28. Rebeck GW, Moir RD, Mui S, Strickland DK, Tanzi RE, Hyman BT. Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. Molecular brain research. 2001 Mar 5;87(2):238-45.
29. T Heneka M, Reyes-Irisarri E, Hull M, P Kummer M. Impact and therapeutic potential of PPARs in Alzheimer's disease. Current neuropharmacology. 2011 Dec 1;9(4):643-50.
30. Rosenberg A, Ngandu T, Rusanen M, Antikainen R, Bäckman L, Havulinna S, Hänninen T, Laatikainen T, Lehtisalo J, Levälahti E, Lindström J. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial. Alzheimer's & Dementia. 2018 Mar;14(3):263-70.
31. Lourida I, Hannon E, Littlejohns TJ, Langa KM, Hyppönen E, Kuźma E, Llewellyn DJ. Association of lifestyle and genetic risk with incidence of dementia. Jama. 2019 Aug 6;322(5):430-7.
32. Rolland Y, Pillard F, Klapouszczak A, Reynish E, Thomas D, Andrieu S, Rivière D, Vellas B. Exercise program for nursing home residents with Alzheimer's disease: A 1‐year randomized, controlled trial. Journal of the American Geriatrics Society. 2007 Feb;55(2):158-65.
33. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychological medicine. 2009 Jan;39(1):3-11.
34. Smith PJ, Blumenthal JA, Hoffman BM, Cooper H, Strauman TA, Welsh-Bohmer K, Browndyke JN, Sherwood A. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosomatic medicine. 2010 Apr;72(3):239.
35. Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane database of systematic reviews. 2015(4).
36. Ströhle A, Schmidt DK, Schultz F, Fricke N, Staden T, Hellweg R, Priller J, Rapp MA, Rieckmann N. Drug and exercise treatment of Alzheimer disease and mild cognitive impairment: a systematic review and meta-analysis of effects on cognition in randomized controlled trials. The American Journal of Geriatric Psychiatry. 2015 Dec 1;23(12):1234-49.
37. Hoffmann K, Sobol NA, Frederiksen KS, Beyer N, Vogel A, Vestergaard K, Brændgaard H, Gottrup H, Lolk A, Wermuth L, Jacobsen S. Moderate-to-high intensity physical exercise in patients with Alzheimer’s disease: a randomized controlled trial. Journal of Alzheimer's Disease. 2016 Jan 1;50(2):443-53.
38. Chapman SB, Aslan S, Spence JS, DeFina LF, Keebler MW, Didehbani N, Lu H. Shorter term aerobic exercise improves brain, cognition, and cardiovascular fitness in aging. Frontiers in aging neuroscience. 2013 Nov 12;5:75.
39. Hibbits N, Pannu R, Wu TJ, Armstrong RC. Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination. ASN neuro. 2009 Aug 3;1(3):AN20090032.
40. Zhang Y, Wang L, Weng Y, Wang D, Wang R, Wang L, Shen S, Wang H, Li Y, Wang Y. Curcumin inhibits hyperandrogen-induced IRE1α-XBP1 pathway activation by activating the PI3K/AKT signaling in ovarian granulosa cells of PCOS model rats. Oxidative medicine and cellular longevity. 2022 Aug 24;2022.
41. Rodriguez-Ayllon M, Solís-Urra P, Arroyo-Ávila C, Álvarez-Ortega M, Molina-García P, Molina-Hidalgo C, Gómez-Río M, Brown B, Erickson KI, Esteban-Cornejo I. Physical activity and amyloid beta in middle-aged and older adults: A systematic review and meta-analysis. Journal of sport and health science. 2023 Aug 7.
42. Yaghoubi A. Changes in Aβ42, Neprilysin, and γ-Secretase in the Hippocampus of Male Rats Alzheimer’s model: The Effects of Aerobic Training and Omega-3 Intake. Journal of Kerman University of Medical Sciences. 2023 Jun 1;30(3):136-45.
43. Kim E, Kim H, Jedrychowski MP, Bakiasi G, Park J, Kruskop J, Choi Y, Kwak SS, Quinti L, Kim DY, Wrann CD. Irisin reduces amyloid-β by inducing the release of neprilysin from astrocytes following downregulation of ERK-STAT3 signaling. Neuron. 2023 Nov 15;111(22):3619-33.
44. Bellettini-Santos T, Batista-Silva H, Marcolongo-Pereira C, Quintela-Castro FC, Barcelos RM, Chiepe KC, Rossoni Jr JV, Passamani-Ambrosio R, da Silva BS, Chiarelli-Neto O, Garcez ML. Move Your Body toward Healthy Aging: Potential Neuroprotective Mechanisms of Irisin in Alzheimer’s Disease. International Journal of Molecular Sciences. 2023 Aug 4;24(15):12440.
45. Mohamad Khanlo N, Shakery N, Gholami M. The effect of 4 weeks of moderate intensity continuous aerobic training on plasma soluble LRP1 levels and brain amyloid beta level in rats with Alzheimer's disease induced by Aβ1-42 injection. Journal of Applied Exercise Physiology. 2019 Jan 21;14(28):117-24.
46. Zarin Afzal M, Kazemzadeh Y, Sedaghati S, Mirzaiyan S, Banaeifar A. The effect of interval training with curcumin supplementation on LRP1 and beta amyloid levels in rats with Alzheimer's disease. EBNESINA 2021; 23 (4) :4-14
47. Misu H, Takayama H, Saito Y, Mita Y, Kikuchi A, Ishii KA, Chikamoto K, Kanamori T, Tajima N, Lan F, Takeshita Y. Deficiency of the hepatokine selenoprotein P increases responsiveness to exercise in mice through upregulation of reactive oxygen species and AMP-activated protein kinase in muscle. Nature medicine. 2017 Apr;23(4):508-16.
48. Jafari M. eroxisome proliferator-activated receptors beta and gamma (PPARβ and PPARγ) genes expression following exercise trainings and high fat diet in male Wistar rats. Journal of Practical Studies of Biosciences in Sport. 2021 Mar 21;9(17):58-67.
49. Shabani M, Salesi M, Daryanoosh F. The effect of high-intensity interval training on the level of peroxisome proliferator-activated receptor gamma and PR domain containing 16 proteins in adipose tissue in overweight type 2 diabetic male Sprague-Dawley rats with diabetes. Pars Journal of Medical Sciences. 2022 Dec 25;16(4):1-9.
50. Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience. 2004 Jan 1;123(1):131-45.
51. Yuan G, Chen X, Li D. Modulation of peroxisome proliferator-activated receptor gamma (PPAR γ) by conjugated fatty acid in obesity and inflammatory bowel disease. Journal of agricultural and food chemistry. 2015 Feb 25;63(7):1883-95.
52. Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B. PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell metabolism. 2007 Aug 8;6(2):137-43.
53. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Frontiers in bioscience: a journal and virtual library. 2008 Jan 1;13:1813.
54. Ballesteros I, Cuartero MI, Pradillo JM, de la Parra J, Pérez-Ruiz A, Corbí Á, Ricote M, Hamilton JA, Sobrado M, Vivancos J, Nombela F. Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARγ and 5-LO-dependent pathways. Journal of leukocyte biology. 2014 Apr;95(4):587-98.
55. Lenglet S, Montecucco F, Mach F. Role of matrix metalloproteinases in animal models of ischemic stroke. Current vascular pharmacology. 2015 Jan 1;13(2):161-6.
56. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nature medicine. 2001 Jan;7(1):48-52.